<DOC>
	<DOCNO>NCT02186834</DOCNO>
	<brief_summary>The main purpose study see whether combination Selinexor ( KPT-330 ) , liposomal doxorubicin dexamethasone help people relapse refractory Multiple Myeloma . Researchers also want find combination Selinexor ( KPT-330 ) , liposomal doxorubicin dexamethasone safe tolerable .</brief_summary>
	<brief_title>Selinexor ( KPT-330 ) Liposomal Doxorubicin For Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients relapse refractory multiple myeloma receive least 2 prior therapy must include lenalidomide proteasome inhibitor . Patients must disease refractory recent therapy . Refractory myeloma define progressive disease within 60 day last therapy . Patients must previously receive ineligible ( refuse ) autologous stem cell transplant . Must measurable myeloma paraprotein level serum ( ≥ 0.5 g/dL ) urine ( ≥ 0.2 g excrete 24hour urine collection sample ) free light chain ( involved free light chain great 100 mg/L ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . ECOG 2 allow due bone disease Must echocardiogram multigated acquisition ( MUGA ) scan indicate leave ventricular ejection fraction ( LVEF ) ≥ 50 % within 42 day prior first dose study drug Adequate hematological function Adequate hepatic function within 14 day prior load phase ( day 14 ) Adequate renal function within 14 day prior load : estimate creatinine clearance ≥ 30 mL/min , ( Cockcroft Gault ) Female patient childbearing potential must agree use dual method contraception negative serum pregnancy test screening . Male patient must use effective barrier method contraception sexually active female childbearing potential . For male female patient , effective method contraception must use throughout study three month follow last dose . Women pregnant lactating Radiation , chemotherapy , immunotherapy approve anticancer therapy ≤2 week prior day 7 ( begin load phase ) Major surgery within four week Day 7 Myocardial infarct within 6 month enrollment , New York Heart Association ( NYHA ) Class II great heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , clinically significant pericardial disease , electrocardiographic evidence acute ischemic active conduction system abnormalities Prior cumulative exposure doxorubicin ( include liposomal preparation ) &gt; 350mg/m^2 Uncontrolled infection require parenteral antibiotic , antiviral , antifungal within one week prior first dose ; patient control infection prophylactic antibiotic permit study Known HIV seropositive Known active hepatitis A , B , C infection ; know positive hepatitis C virus ( HCV ) RNA HBsAg ( HBV surface antigen ) Any underlying condition would significantly interfere absorption oral medication Grade &gt; 2 peripheral neuropathy baseline ( within 14 day prior load phase ( day 7 ) ) Serious psychiatric medical condition could interfere treatment Participation investigational anticancer study within 3 week prior day 7 ( begin load phase ) Concurrent therapy approve investigational anticancer therapeutic Coagulation problem active bleed last month Previous allogeneic transplant within 6 month evidence clinically significant graft versus host disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Myeloma</keyword>
</DOC>